M Fléron

ORCID: 0009-0008-6911-239X
Publications
Citations
Views
---
Saved
---
About
Contact & Profiles
Research Areas
  • Advanced Proteomics Techniques and Applications
  • Mass Spectrometry Techniques and Applications
  • Advanced Biosensing Techniques and Applications
  • Transcranial Magnetic Stimulation Studies
  • Peripheral Nerve Disorders
  • Motor Control and Adaptation
  • Inflammatory Bowel Disease
  • Cystic Fibrosis Research Advances
  • Chronic Obstructive Pulmonary Disease (COPD) Research
  • Biosensors and Analytical Detection
  • Immunodeficiency and Autoimmune Disorders
  • Advanced biosensing and bioanalysis techniques
  • Chronic Lymphocytic Leukemia Research
  • Microscopic Colitis
  • Eosinophilic Esophagitis
  • RNA and protein synthesis mechanisms
  • Cardiac, Anesthesia and Surgical Outcomes
  • Pulmonary Hypertension Research and Treatments
  • Gold and Silver Nanoparticles Synthesis and Applications
  • Autoimmune and Inflammatory Disorders
  • Esophageal and GI Pathology
  • Gastrointestinal disorders and treatments
  • Aortic Disease and Treatment Approaches

University of Liège
1981-2025

Hospital de Clínicas de Porto Alegre
2020

Modification of soleus and anterior tibial horn cell excitability following ipsilateral contralateral stimulations the sural nerve was studied by either H reflex (for muscles) or F response muscles). Several intensities stimulation were employed. In every instance recovery curves showed two distinct peaks facilitation, which appeared with same delay in muscles antagonist functions. Also, reciprocal facilitation inhibition phenomena occurred after a 25 ms lasted more than 1000 observed. The...

10.1136/jnnp.44.8.699 article EN Journal of Neurology Neurosurgery & Psychiatry 1981-08-01

Abstract Background Increased permeability, mucosal barrier and epithelial anomalies (crypt distortion, wider crypt lumen, gaps) as well altered tight junctions have been described in active ulcerative colitis (UC) Crohn’s Disease (CD). Probe based Confocal laser endomicroscopy (pCLE) is able to monitor vivo1. This study aimed at comparing the proteomic profiles of colonic epithelium associated with pCLE UC, CD non-IBD subjects. Methods Biopsies were collected IBDs endoscopic remission...

10.1093/ecco-jcc/jjae190.0220 article EN Journal of Crohn s and Colitis 2025-01-01

Proteomics, essential for understanding gene and cell functions, faces challenges with peptide loss due to adsorption onto vial surfaces, especially in samples low quantities. Using HeLa tryptic digested standard solutions, we demon-strate preferential of peptides, particularly hydrophobic ones, polypropylene (PP) vials, leading non-uniform signal loss. This phenomenon can alter protein quantification (e.g., label-free quantification, LFQ) if no appropriat-ed data processing is applied. Our...

10.26434/chemrxiv-2024-dw5zg preprint EN cc-by-nc-nd 2024-03-01

Proteomics, essential for understanding gene and cell functions, faces challenges with peptide loss due to adsorption onto vial surfaces, especially in samples low quantities. Using HeLa tryptic digested standard solutions, we demon-strate preferential of peptides, particularly hydrophobic ones, polypropylene (PP) vials, leading non-uniform signal loss. This phenomenon can alter protein quantification (e.g., Label-Free Quantification, LFQ) if no appropri-ated data processing is applied. Our...

10.26434/chemrxiv-2024-dw5zg-v2 preprint EN 2024-07-12

Abstract Background Ileal and colonic Crohn’s disease (CD) are nowadays considered as separate entities. Studies needed to better characterise the biological specificities of these subphenotypes. In fine, this research should offer opportunities for development personalised medicine. Methods By combining different technologies (proximity extension assay, selected reaction monitoring high-sensitivity turbidimetric immunoassay (hsCRP)), 207 serum proteins were measured in CD patients...

10.1093/ecco-jcc/jjad212.0527 article EN Journal of Crohn s and Colitis 2024-01-01

Abstract Background In Crohn’s disease (CD) patients stopping infliximab (IFX), the risk of short-term relapse (<6 months) and mid/long-term (>6 were associated with distinct biological profiles (STORI trial). Herein, we aim to test external validity this finding in an independent trial (SPARE). Methods The SPARE has included 211 CD (from 64 sites Europe Australia) steroid-free remission >6 months, receiving a combined therapy (IFX immunosuppressant (IS)) >8...

10.1093/ecco-jcc/jjac190.0002 article EN Journal of Crohn s and Colitis 2023-01-30
Coming Soon ...